Eprosartan Mesylate - CAS 144143-96-4
Catalog number: 144143-96-4
Category: Inhibitor
Not Intended for Therapeutic Use. For research use only.
Molecular Formula:
Molecular Weight:
Angiotensin Receptor
Eprosartan is a nonpeptide angiotensin II receptor antagonist, [3H]-eprosartan binds to the AT1 receptor with KD of 0.83 nM in rat vascular smooth muscle cells.
Publictions citing BOC Sciences Products
  • >> More
1.The angiotensin receptor blocker eprosartan mesylate reduces pulse pressure in isolated systolic hypertension.
Teitelbaum I1, Chilvers M, Reiz RJ. Can J Cardiol. 2004 Oct;20 Suppl C:11C-16C.
BACKGROUND: Isolated systolic hypertension (ISH) is a common and particularly poorly controlled form of hypertension.
2.Determination of eprosartan mesylate and hydrochlorothiazide in tablets by derivative spectrophotometric and high-performance liquid chromato
Hacioğlu F1, Onal A. J Chromatogr Sci. 2012 Sep;50(8):688-93. doi: 10.1093/chromsci/bms037. Epub 2012 May 10.
Two new simple and selective assay methods have been presented for the analysis of eprosartan mesylate (EPR) and hydrochlorothiazide (HCT) in pharmaceutical formulations. The first method is based on first-derivative ultraviolet spectrophotometry with zero-crossing measurements at 246 and 279 nm for EPR and HCT, respectively. The assay was linear over the concentration ranges 3.0-14.0 µg/mL for EPR and 1.0-12.0 µg/mL for HCT. The quantification limits for EPR and HCT were found to be 1.148 and 0.581 µg/mL, respectively, while the detection limits were 0.344 µg/mL for EPR and 0.175 µg/mL for HCT. The second method involved isocratic reversed-phase liquid chromatography using a mobile phase composed of acetonitrile-10 mM phosphoric acid (pH 2.5) (40:60, v/v). Olmesartan was used as internal standard and the substances were detected at 272 nm. The linearity ranges were found to be 0.5-30 and 0.3-15.0 µg/mL for EPR and HCT, respectively. The limits of detection were found to be 0.
3.Once-daily eprosartan mesylate in the treatment of elderly patients with isolated systolic hypertension: data from a 13-week double-blind, pl
Punzi HA1, Punzi CF. J Hum Hypertens. 2004 Sep;18(9):655-61.
This was a double-blind, randomized, placebo-controlled multicenter, titration-to-effect study of eprosartan in patients > or =60 years of age with isolated systolic hypertension. The study consisted of a 3 to 5-week placebo run-in period, a 13-week double-blind treatment period (6-week titration with eprosartan 600-1200 mg/day, 3-week maintenance, 4-week combination therapy with hydrochlorothiazide/HCTZ 12.5 mg), and a follow-up period within 5-7 days of last treatment dose. Overall, 283 patients (placebo/P: 135; eprosartan /E: 148) were randomized [female patients-P: 55.6%, E:54.7%; white-P:66.7%, E:67.6%). Mean sitting systolic blood pressure (SitSBP) at baseline was comparable (P: 170+/-0.8 mmHg; E: 171+/-0.8 mm Hg). At monotherapy end point, eprosartan produced a significant reduction in SitSBP (E: 16.1 mmHg vs P: 8.4 mmHg; P<0.0001). In all, 57.4% of patients responded to eprosartan monotherapy. Among nonresponders, the addition of HCTZ resulted in a decrease in SitSBP from baseline (E: 21.
4.Quality by design: a systematic and rapid liquid chromatography and mass spectrometry method for eprosartan mesylate and its related impuriti
Kalariya PD1, Kumar Talluri MV, Gaitonde VD, Devrukhakar PS, Srinivas R. J Sep Sci. 2014 Aug;37(16):2160-71. doi: 10.1002/jssc.201301364. Epub 2014 Jul 10.
The present work describes the systematic development of a robust, precise, and rapid reversed-phase liquid chromatography method for the simultaneous determination of eprosartan mesylate and its six impurities using quality-by-design principles. The method was developed in two phases, screening and optimization. During the screening phase, the most suitable stationary phase, organic modifier, and pH were identified. The optimization was performed for secondary influential parameters--column temperature, gradient time, and flow rate using eight experiments--to examine multifactorial effects of parameters on the critical resolution and generated design space representing the robust region. A verification experiment was performed within the working design space and the model was found to be accurate. This study also describes other operating features of the column packed with superficially porous particles that allow very fast separations at pressures available in most liquid chromatography instruments.
Molecular Weight Calculator Molarity Calculator Solution Dilution Calculator

Related Angiotensin Receptor Products

CAS 127060-75-7 CGP-42112A

(CAS: 127060-75-7)

CGP-42112A, an angiotensin AT2 receptor agonist which could probably lead to the inhibition of ATPase and contraction of aortic rings in rabbit.

CAS 34273-10-4 Saralasin

(CAS: 34273-10-4)

Saralasin is a competitive and nonselective angiotensin II receptor antagonist.

CAS 863031-24-7 Azilsartan medoxomil monopotassium

Azilsartan medoxomil monopotassium
(CAS: 863031-24-7)

Azilsartan medoxomil monopotassium is an azilsartan prodrug and and an orally administered angiotensin II receptor type 1 antagonist with IC50 of 0.62 nM. It is...

CAS 138402-11-6 Irbesartan

(CAS: 138402-11-6)

Irbesartan (SR-47436, BMS-186295) is a highly potent and specific angiotensin II type 1 (AT1) receptor antagonist with IC50 of 1.3 nM.

CAS 147403-03-0 Azilsartan Medoxomil

Azilsartan Medoxomil
(CAS: 147403-03-0)

Azilsartan (TAK-536) is an angiotensin II receptor antagonist used in the treatment of hypertension.

CAS 124750-99-8 Losartan Potassium (DuP 753)

Losartan Potassium (DuP 753)
(CAS: 124750-99-8)

Losartan is an angiotensin II receptor antagonist that competes with the binding of angiotensin II to AT1 receptors with IC50 of 20 nM. It promotes vasodilatati...

MK 996
(CAS: 157263-00-8)

MK-996, an imidazopyridine derivative, has been found to be an angiotensin receptor antagonist that was once developed in the treatment of hypertension by Merck...

CAS 159432-28-7 A 779

A 779
(CAS: 159432-28-7)

A 779 is a specific antagonist of G-protein coupled receptor (Mas receptor) (IC50= 0.3 nM) with no significant affinity for AT1 or AT2 receptors at a concentrat...

CAS 53902-12-8 Tranilast

(CAS: 53902-12-8)

Tranilast, also called Rizaben or Tranilastum, has anti-inflammatory and immunomodulatory effect. It binds to Aβ40 monomers and increases Aβ40 fibrillation.

CAS 146709-78-6 ZD 7155 hydrochloride

ZD 7155 hydrochloride
(CAS: 146709-78-6)

ZD 7155 hydrochloride is a potent, selective and competitive antagonist for the angiotensin II type 1 (AT1) receptor. ZD 7155 hydrochloride displaces [125I]-ang...

CAS 130663-39-7 PD123319

(CAS: 130663-39-7)

PD 123319 is a potent, selective AT2 angiotensin II receptor antagonist with IC50 of 34 nM.

(CAS: 254740-64-2)

Sparsentan, also known as RE-021, BMS346567, is a dual antagonist of both angiotensin II and endothelin A receptor antagonist.

CAS 144689-63-4 Olmesartan Medoxomil

Olmesartan Medoxomil
(CAS: 144689-63-4)

Olmesartan Medoxomil is a compound which is hydrolyzed to olmesartan that is a selective AT1 subtype angiotensin II receptor antagonist.

CAS 159748-08-0 LY285434

(CAS: 159748-08-0)

An antagonist of angiotensin II receptor

CAS 936623-90-4 LCZ696

(CAS: 936623-90-4)

LCZ696 is a potent ARNi inhibitor and an investigational drug to treat heart failure. Chemically, LCZ696 is a mixture of valsartan and sacubitril in a 1:1 mol...

CAS 133085-33-3 BIBS 39

(CAS: 133085-33-3)

BIBS 39, a nonpeptide angiotensin II receptor antagonist, has been found to exhibit potential antihypertensive activity in rat. It has been already discontinued...

CAS 477775-14-7 M 24

M 24
(CAS: 477775-14-7)

M 24 is the first selective AT2 receptor agonist (Ki 0.4nM and 10.000 nM for AT2 and AT1 respectively). M 24 effects against endothelial inflammation and leukoc...

CAS 156001-18-2 Embusartan

(CAS: 156001-18-2)

Embusartan, an oxopyridine derivative, has been found to be an angiotensin II receptor antagonist that was once studied against hypertension by Bayer.

CAS 1216884-39-7 EMD 66684

EMD 66684
(CAS: 1216884-39-7)

EMD 66684 is a potent and selective non-peptide angiotensin AT1 receptor antagonist (IC50 = 0.7 and > 10000 nM for AT1 and AT2 receptors, respectively). It inhi...

CAS 139481-59-7 Candesartan

(CAS: 139481-59-7)

Candesartan (10 mg/kg) inhibits the growth of engrafted tumors and reduces the microvessel density and VEGF expression in a mouse KU-19-19 xenograft model

Chemical Structure

CAS 144143-96-4 Eprosartan Mesylate

Quick Inquiry

Verification code

Featured Items